FORM 4

## **UNITED STATES SECU**

Washington, D.C. 20549

Jh	KI I	IES	AND	EXCI	HANG	F C	)MIMI	1551	ON

OMB AF	PROVAL
OMB Number:	3235-0287

- 1		
	OMB Number:	3235-0287
	Estimated average	burden
	hours per response	: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). S	ee Instruction 1	0.																	
1. Name ar <u>Tyagar</u>	2. Issuer Name and Ticker or Trading Symbol Candel Therapeutics, Inc. [ CADL ]							5. Relationship of Reportin (Check all applicable) Director Officer (give title			10% Ow		vner						
(Last) (First) (Middle) C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450						3. Date of Earliest Transaction (Month/Day/Year) 11/29/2024								Officer (give title Other (specify below) below)  Chief Technology Officer					
(Street) NEEDHAM MA 02494  (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person     Form filed by More than One Reporting Person					
		Table	I - No	on-Deriva	tive S	Secu	rities	Acc	quirec	d, Dis	posed of	, or E	Bene	ficial	ly Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/					Execution Date,		,	3. Transaction Code (Instr. 8)					and 5) Securi		ties cially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) o	r Pr	ice	Transa	ansaction(s) str. 3 and 4)			,iiisu. 4 <i>)</i>	
Common Stock 11/29/20						)24			S		20,392(1)	D	D \$4.5		56 125,657			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			4. Transa Code ( 8)			Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		str.	. Price of lerivative lecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amor or Numl of Share	ber					

## **Explanation of Responses:**

1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

/s/ Charles Schoch, as

Attorney-in-Fact for Seshu 12/03/2024

<u>Tyagarajan</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.